Aldeyra Reports Positive Phase IIa Results for Dry Eye Candidate ADX-102

September 15, 2017: By Joan McKenna

aldeyra_logoAldeyra Therapeutics announced Sept. 12 that its lead drug candidate, ADX-102, showed positive results in a Phase IIa dose-ranging clinical trial for dry eye disease.

The Lexington, Massachusetts, company said ADX-2012 showed statistically and clinically significant improvement across multiple sign and symptom endpoints, with onset of action within one week.

ADX-102 is an aldehyde trap intended to treat ocular inflammation. ADX-102 has been tested in more than 250 patients in Phase II trials in dry eye, allergic conjunctivitis, and noninfectious anterior uveitis.

In the dry eye study, levels of malondialdehyde, a pro-inflammatory aldehyde mediator sequestered by ADX-102, were significantly reduced in the tears of patients, Aldeyra said. There were no safety concerns or serious adverse events.

The company said it plans to initiate a Phase IIb clinical trial in dry eye in the first half of 2018.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Imprimis Offers Compounded Alternative to Restasis for Dry Eye

US District Court Invalidates Four Restasis Patents

BioTime Prices $25 Million Public Offering of Common Stock

Gemini Completes $42.5 Million Series A Financing for Dry AMD Treatment

BIOPHYTIS Raises €10.4 Million to Develop Anti-Aging Drugs, One for Dry AMD

Amydis Receives $530 Thousand NIH Award to Advance Ophthalmic Diagnostic Probes

Realm Announces Completion of $26 million Private Placement

Sight Sciences Secures $10 Million in Oversubscribed Series C Financing

Aerpio Names Stephen Hoffman CEO; Founder Joseph Gardner Remains President

FDA Advisory Panel Recommends Aerie’s Rhopressa for Glaucoma Patients

FDA Panel Unanimously Backs Spark’s Luxturna as Retinal Gene Therapy

PanOptica Secures $11 Million to Advance Topical Anti-VEGF Eye Drop for Neovascular AMD

Nicox and pSivida to Collaborate to Develop a Sustained Release Drug to Lower IOP

Azura Nets $16 Million in Series B Funding for Dry Eye Treatment

Alcon’s AcrySof Intraocular Lens Reaches 100 Million Implants

Notal Vision’s ForeseeHome Reaches Milestone of 3 Million Tests

FDA to Review Spark’s Retinal Gene Therapy Candidate Oct. 12

Alcon’s AutonoMe IOL Injector Gains CE Mark Approval

Shire Sues Allergan, Claiming Bundling Tactics Block Restasis Competitors

Allergan Decries ‘Unfair’ Patent Challenge Process as US House Launches Probe of Tribe Deal

Coming soon

2017 Refractive Surgery Report: A Global Market Analysis for 2016 to 2022